Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330068 · ClinicalTrials.gov registry record
Microbiome of Depression & Treatment Response to Citalopram
A clinical trial of Major Depressive Disorder, Bipolar I and Bipolar II, sponsored by Mayo Clinic.
- Completed
- Registry status
- 34
- Enrollment target
- 2
- Study locations
NCT02330068: Completed study of Major Depressive Disorder, Bipolar I and Bipolar II, sponsored by Mayo Clinic.
NCT02330068 is a study of Major Depressive Disorder, Bipolar I and Bipolar II that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330068, a study of Major Depressive Disorder, Bipolar I and Bipolar II, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will enroll approximately 80 participants (anticipated 40 study completers with paired biomarker data) with an episode of major depression, Bipolar I or Bipolar II and 40 age- and sex-matched healthy controls.
Primary Outcome
The gut microbiome of depressed patients is different from that of age-, sex-, menopause-, and BMI-matched healthy controls
Conditions Studied
Interventions
- DRUG citalopram
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-12 |
What the finished NCT02330068 record still lists
NCT02330068 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 1 condition, with Major Depressive Disorder, Bipolar I and Bipolar II appearing as the primary indexed condition, and to 1 intervention - of which citalopram is the first listed.
NCT02330068 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02330068 about?
NCT02330068 is a clinical study titled "Microbiome of Depression & Treatment Response to Citalopram". The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will ...
What is the current status of trial NCT02330068?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2014-12. Estimated completion is 2017-12.
What conditions does trial NCT02330068 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Bipolar I and Bipolar II.
What interventions are being tested in trial NCT02330068?
The interventions under investigation include: citalopram (DRUG).
Who is sponsoring clinical trial NCT02330068?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330068 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia